A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 413 participants.
Also called NCT01392573
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 413 participants
- Sponsor
- Registry
-
NCT01392573 -
2011-002336-72
-
- Other papers using this trial's data
- A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges
- Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)
- EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Denmark, Hungary, India, Slovenia, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT01392573. Randomized; double masking; primary purpose treatment. Start 2011-11-28 (actual); primary completion 2012-10-01 (actual). Results posted on 2017-01-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
- Acronym
- DUAL™ II
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/liraglutide
- Intervention (Drug)
- insulin degludec
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01392573- Content hash
a026149c3de130bc7bb46b828886e20ba5367f658d17ae80c136f979608d251f